Craft

Sun Pharma

Stock Price

₹1.5 K

2024-05-21

Market Capitalization

₹3.6 T

2024-05-21

Revenue

₹432.8 B

FY, 2023

Sun Pharma Summary

Company Summary

Overview
Sun Pharma is the fifth largest speciality generic pharmaceutical company in the world. We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries. It is also India’s largest, most trusted, and most valuable pharmaceuticals company by market capitalisation. Our global revenues exceed US$ 4.6 billion. We attribute our growth and success to our over 30,000 strong multi-cultural workforce from over 50 different nationalities. Our team has taken Sun Pharma to the heights that it has scaled and are now working to take it further up on its high growth trajectory. Our people are our most valuable asset. Our culturally diverse workforce is one of our biggest strengths and the rich experience they bring, across varied skill-sets and backgrounds, is invaluable. We are proud that our global workforce is bound together by our common values.
Type
Public
Status
Active
Founded
1983
HQ
Mumbai, IN | view all locations
Website
http://www.sunpharma.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Israel Makov

    Israel Makov, Chairman

    • Dilip Shanghvi

      Dilip Shanghvi, Managing Director

      LocationsView all

      1 location detected

      • Mumbai, MH HQ

        India

        SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E)

      Sun Pharma Financials

      Summary Financials

      Revenue (Q3, 2024)
      ₹121.6B
      Gross profit (Q3, 2024)
      ₹98.9B
      Net income (Q3, 2024)
      ₹25.7B
      Cash (Q2, 2024)
      ₹72.2B
      EBIT (Q3, 2024)
      ₹29.1B
      Enterprise value
      $3.6T

      Footer menu